Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries

详细信息    查看全文

• 作者：Ignacio Garcia-Doval ; MD ; PhD^a ; ^b ; ^{Ignacio.garcia.doval@sergas.es} ; Arnon D. Cohen ; MD ; PhD^c ; ^d ; Simone Cazzaniga ; PhD^e ; Ilan Feldhamer ; PhD^c ; ^d ; Antonio Addis ; PharmD ; PhD^f ; Gregorio Carretero ; MD^g ; Carlos Ferrá ; ndiz ; MD ; PhD^h ; Robert S. Stern ; MDⁱ ; Luigi Naldi ; MD ; PhD^e ; on behalf of the Psonet Network
• 关键词：anti-inflammatory agents ; anti&ndash ; tumor necrosis factor ; biological agents ; immunosuppressive agents ; psoriasis/drug therapy ; safety
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：76
• 期：2
• 页码：299-308.e16
• 全文大小：819 K
• 卷排序：76

文摘

Anti–tumor necrosis factor (TNF) therapy in psoriasis has been associated with an increased risk of serious infections compared with nonbiologic systemic therapies.ObjectiveWe sought to quantify the risk of: (1) serious infections (leading to hospitalization, sequelae, or death); and (2) “any infection,” bacterial cutaneous infections, and granulomatous infections among patients receiving anti–TNF therapy compared with nonbiologics (acitretin, methotrexate, cyclosporine).MethodsWe used prospective meta-analysis to combine data from the Psocare registry (Italy), Biobadaderm registry (Spain), and Clalit Health Services database (Israel), including 17,739 patients and 23,357.5 person-years of follow-up.ResultsFor serious infections, age, gender, and Charlson morbidity index adjusted hazard ratio of exposure to anti–TNFs compared with nonbiologics was 0.98 (95% confidence interval 0.80-1.19), for bacterial cutaneous infections it was 1.00 (95% confidence interval 0.62-1.61), and for granulomatous infections it was 1.23 (95% confidence interval 0.82-1.84). Using methotrexate as comparator and comparing first year of exposure with later exposure did not modify the results. For any infectious episode, risks and relative risks were heterogeneous among registries, probably because of different definitions of outcome.LimitationsThere was lack of power to describe risk of single drugs.ConclusionIn current clinical practice, treatment with anti–TNF drugs was not associated with a higher risk of serious infections than treatment with nonbiologic systemic therapy.